|
    |
Attention Deficit Hyperactivity Disorder Consensus Development Conference Statement November 16-18, 1998
This statement is more than five years old and is provided solely for historical purposes. Due to the cumulative nature of medical research, new knowledge has inevitably accumulated in this subject area in the time since the statement was initially prepared. Thus some of the material is likely to be out of date, and at worst simply wrong. For reliable, current information on this and other health topics, we recommend consulting the National Institutes of Health's MedlinePlus http://www.nlm.nih.gov/medlineplus/. This statement was originally published as: Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder. NIH Consens Statement 1998 Nov 16-18; 16(2): 1-37. For making bibliographic reference to consensus statement no. 110 in the electronic form displayed here, it is recommended that the following format be used: Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder. NIH Consens Statement Online 1998 Nov 16-18; [cited year, month, day]; 16(2): 1-37. AbstractObjectiveThe objective of this NIH Consensus Statement is to inform the biomedical research and clinical practice communities of the results of the NIH Consensus Development Conference on Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder (ADHD). The statement provides state-of-the-art information regarding effective treatments for ADHD and presents the conclusions and recommendations of the consensus panel regarding these issues. In addition, the statement identifies those areas of study that deserve further investigation. Upon completion of this educational activity, the reader should possess a clear working clinical knowledge of the state of the art regarding this topic. The target audience of clinicians for this statement includes, but is not limited to, psychiatrists, family practitioners, pediatricians, internists, neurologists, psychologists, and behavioral medicine specialists. ParticipantsParticipants were a non-Federal, nonadvocate, 13-member panel representing the fields of psychology, psychiatry, neurology, pediatrics, epidemiology, biostatistics, education, and the public. In addition, 31 experts from these same fields presented data to the panel and a conference audience of 1215. EvidenceThe literature was searched through Medline, and an extensive bibliography of references was provided to the panel and the conference audience. Experts prepared abstracts with relevant citations from the literature. Scientific evidence was given precedence over clinical anecdotal experience. Consensus ProcessThe panel, answering predefined questions, developed their conclusions based on the scientific evidence presented in open forum and the scientific literature. The panel composed a draft statement that was read in its entirety and circulated to the experts and the audience for comment. Thereafter, the panel resolved conflicting recommendations and released a revised statement at the end of the conference. The panel finalized the revisions within a few weeks after the conference. The draft statement was made available on the World Wide Web immediately following its release at the conference and was updated with the panel's final revisions. ConclusionsAttention deficit hyperactivity disorder or ADHD is a commonly diagnosed behavioral disorder of childhood that represents a costly major public health problem. Children with ADHD have pronounced impairments and can experience long-term adverse effects on academic performance, vocational success, and social-emotional development which have a profound impact on individuals, families, schools, and society. Despite progress in the assessment, diagnosis, and treatment of ADHD, this disorder and its treatment have remained controversial, especially the use of psychostimulants for both short- and long-term treatment. Although an independent diagnostic test for ADHD does not exist, there is evidence supporting the validity of the disorder. Further research is needed on the dimensional aspects of ADHD, as well as the comorbid (coexisting) conditions present in both childhood and adult forms. Studies (primarily short term, approximately 3 months), including randomized clinical trials, have established the efficacy of stimulants and psychosocial treatments for alleviating the symptoms of ADHD and associated aggressiveness and have indicated that stimulants are more effective than psychosocial therapies in treating these symptoms. Because of the lack of consistent improvement beyond the core symptoms and the paucity of long-term studies (beyond 14 months), there is a need for longer term studies with drugs and behavioral modalities and their combination. Although trials are under way, conclusive recommendations concerning treatment for the long term cannot be made presently. There are wide variations in the use of psychostimulants across communities and physicians, suggesting no consensus regarding which ADHD patients should be treated with psychostimulants. These problems point to the need for improved assessment, treatment, and followup of patients with ADHD. A more consistent set of diagnostic procedures and practice guidelines is of utmost importance. Furthermore, the lack of insurance coverage preventing the appropriate diagnosis and treatment of ADHD and the lack of integration with educational services are substantial barriers and represent considerable long-term costs for society. Finally, after years of clinical research and experience with ADHD, our knowledge about the cause or causes of ADHD remains largely speculative. Consequently, we have no documented strategies for the prevention of ADHD. IntroductionAttention deficit hyperactivity disorder (ADHD) is the most commonly diagnosed behavioral disorder of childhood, estimated to affect 3 to 5 percent of school-age children. Its core symptoms include developmentally inappropriate levels of attention, concentration, activity, distractibility, and impulsivity. Children with ADHD usually have functional impairment across multiple settings including home, school, and peer relationships. ADHD has also been shown to have long-term adverse effects on academic performance, vocational success, and social-emotional development. Despite the progress in the assessment, diagnosis, and treatment of children and adults with ADHD, the disorder has remained controversial. The diverse and conflicting opinions about ADHD have resulted in confusion for families, care providers, educators, and policymakers. The controversy raises questions concerning the literal existence of the disorder, whether it can be reliably diagnosed, and, if treated, what interventions are the most effective. One of the major controversies regarding ADHD concerns the use of psychostimulants to treat the condition. Psychostimulants, including amphetamine, methylphenidate, and pemoline, are by far the most widely researched and commonly prescribed treatments for ADHD. Because psychostimulants are more readily available and are being prescribed more frequently, concerns have intensified over their potential overuse and abuse. This 2 1/2 day conference brought together national and international experts in the fields of relevant medical research and health care as well as representatives from the public. After 1 1/2 days of presentations and audience discussion, an independent, non-Federal consensus panel chaired by Dr. David J. Kupfer, Thomas Detre Professor and Chair, Department of Psychiatry, University of Pittsburgh, weighed the scientific evidence and wrote a draft statement that was presented to the audience on the third day. The consensus statement addressed the following key questions:
The primary sponsors of this conference were the National Institute on Drug Abuse, the National Institute of Mental Health, and the National Institutes of Health (NIH) Office of Medical Applications of Research. The conference was cosponsored by the National Institute of Environmental Health Sciences, the National Institute of Child Health and Human Development, the U.S. Food and Drug Administration, and the Office of Special Education Programs, U.S. Department of Education. 1. What Is the Scientific Evidence To Support ADHD as a Disorder?The diagnosis of ADHD can be made reliably using well-tested diagnostic interview methods. However, as of yet, there is no independent valid test for ADHD. Although research has suggested a central nervous system basis for ADHD, further research is necessary to firmly establish ADHD as a brain disorder. This is not unique to ADHD, but applies as well to most psychiatric disorders, including disabling diseases such as schizophrenia. Evidence supporting the validity of ADHD includes the long-term developmental course of ADHD over time, cross-national studies revealing similar risk factors, familial aggregation of ADHD (which may be genetic or environmental), and heritability. Additional efforts to validate the disorder are needed: careful description of the cases, use of specific diagnostic criteria, repeated followup studies, family studies (including twin and adoption studies), epidemiologic studies, and long-term treatment studies. To the maximum extent possible, such studies should include various controls, including normal subjects and those with other clinical disorders. Such studies may provide suggestions about subgrouping of patients that will turn out to be associated with different outcomes, responses to different treatment, and varying patterns of familial characteristics and illnesses. Certain issues about the diagnosis of ADHD have been raised that indicate the need for further research to validate diagnostic methods.
2. What Is the Impact of ADHD on Individuals, Families, and Society?Families who have children with ADHD, as with other behavioral disorders and chronic diseases, experience increased levels of parental frustration, marital discord, and divorce. In addition, the direct costs of medical care for children and youth with ADHD are substantial. These costs represent a serious burden for many families because they frequently are not covered by health insurance. In the larger world, these individuals consume a disproportionate share of resources and attention from the health care system, criminal justice system, schools, and other social service agencies. Methodological problems preclude precise estimates of the cost of ADHD to society. However, these costs are large. For example, additional national public school expenditures on behalf of students with ADHD may have exceeded $3 billion in 1995. Moreover, ADHD, often in conjunction with coexisting conduct disorders, contributes to societal problems such as violent crime and teenage pregnancy. Families of children impaired by the symptoms of ADHD are in a very difficult position. The painful decision-making process to determine appropriate treatment for these children is often made substantially worse by the media war between those who overstate the benefits of treatment and those who overstate the dangers of treatment. 3. What Are the Effective Treatments for ADHD?A wide variety of treatments have been used for ADHD including, but not limited to, various psychotropic medications, psychosocial treatment, dietary management, herbal and homeopathic treatments, biofeedback, meditation, and perceptual stimulation/training. Of these treatment strategies, stimulant medications and psychosocial interventions have been the major foci of research. Studies on the efficacy of medication and psychosocial treatments for ADHD have focused primarily on a condition equivalent to DSM-IV combined type, meeting criteria for Inattention and Hyperactivity/Impulsivity. Until recently, most randomized clinical trials have been short term, up to approximately 3 months. Overall, these studies support the efficacy of stimulants and psychosocial treatments for ADHD and the superiority of stimulants relative to psychosocial treatments. However, there are no long-term studies testing stimulants or psychosocial treatments lasting several years. There is no information on the long-term outcomes of medication-treated ADHD individuals in terms of educational and occupational achievements, involvement with the police, or other areas of social functioning. Several short-term studies of antidepressants show that desipramine produces improvements over placebo in parent and teacher ratings of ADHD symptoms. Results from studies examining the efficacy of imipramine are inconsistent. Although a number of other psychotropic medications have been used to treat ADHD, the extant outcome data from these studies do not allow for conclusions regarding their efficacy. Psychosocial treatment of ADHD has included a number of behavioral strategies such as contingency management (e.g., point/token reward systems, timeout, response cost) that typically is conducted in the classroom, parent training (where the parent is taught child management skills), clinical behavior therapy (parent, teacher, or both are taught to use contingency management procedures), and cognitive-behavioral treatment (e.g., self-monitoring, verbal self-instruction, problem-solving strategies, self-reinforcement). Cognitive-behavioral treatment has not been found to yield beneficial effects in children with ADHD. In contrast, clinical behavior therapy, parent training, and contingency management have produced beneficial effects. Intensive direct interventions in children with ADHD have produced improvements in key areas of functioning. However, no randomized control trials have been conducted on some of these intensive interventions alone or in combination with medication. Studies that compared stimulants with psychosocial treatment consistently reported greater efficacy of stimulants. Emerging data suggest that medication using systematic titration and intensive monitoring methods over a period of approximately 1 year is superior to an intensive set of behavioral treatments on core ADHD symptoms (inattention, hyperactivity/impulsivity, aggression). Combined medication and behavioral treatment added little advantage overall, over medication alone, but combined treatment did result in more improved social skills, and parents and teachers judged this treatment more favorably. Both systematically applied medication (monitored regularly) and combined treatment were superior to routine community care, which often involved the use of stimulants. An important potential advantage for behavioral treatment is the possibility of improving functioning with reduced dose of stimulants. This possibility was not tested. There is a long history of a number of other interventions for ADHD. These include dietary replacement, exclusion, or supplementation; various vitamin, mineral, or herbal regimens; biofeedback; perceptual stimulation; and a host of others. Although these interventions have generated considerable interest and there are some controlled and uncontrolled studies using various strategies, the state of the empirical evidence regarding these interventions is uneven, ranging from no data to well-controlled trials. Some of the dietary elimination strategies showed intriguing results suggesting the need for future research. The current state of the empirical literature regarding the treatment of ADHD is such that at least five important questions cannot be answered. First, it cannot be determined if the combination of stimulants and psychosocial treatments can improve functioning with reduced dose of stimulants. Second, there are no data on the treatment of ADHD, Inattentive type, which might include a high percentage of girls. Third, there are no conclusive data on treatment in adolescents and adults with ADHD. Fourth, there is no information on the effects of long-term treatment (treatment lasting more than 1 year), which is indicated in this persistent disorder. Finally, given the evidence about the cognitive problems associated with ADHD, such as deficiencies in working memory and language processing deficits, and the demonstrated ineffectiveness of current treatments in enhancing academic achievement, there is a need for application and development of methods targeted to these weaknesses. 4. What Are the Risks of the Use of Stimulant Medication and Other Treatments?Although little information exists concerning the long-term effects of psychostimulants, there is no conclusive evidence that careful therapeutic use is harmful. When adverse drug reactions do occur, they are usually related to dose. Effects associated with moderate doses may include decreased appetite and insomnia. These effects occur early in treatment and may decrease with continued dosing. There may be negative effects on growth rate, but ultimate height appears not to be affected. It is well known that psychostimulants have abuse potential. Very high doses of psychostimulants, particularly of amphetamines, may cause central nervous system damage, cardiovascular damage, and hypertension. In addition, high doses have been associated with compulsive behaviors and, in certain vulnerable individuals, movement disorders. There is a rare percentage of children and adults treated at high doses who have hallucinogenic responses. Drugs used for ADHD other than psychostimulants have their own adverse reactions: tricyclic antidepressants may induce cardiac arrhythmias, bupropion at high doses can cause seizures, and pemoline is associated with liver damage. The degree of assessment and followup by primary care physicians varies significantly. This variance may contribute to the marked differences in appropriate prescribing practices. Adequate followup is required for any prescribed medications, especially for higher doses of psychostimulants. Although an increased risk of drug abuse and cigarette smoking is associated with childhood ADHD (see Question 2), existing studies come to conflicting conclusions as to whether use of psychostimulants increases or decreases the risk of abuse. A major limitation of inferences from observational databases is the inability to examine independently the use of stimulant medication, the diagnosis and severity of ADHD, and the effect of coexisting conditions. The increased availability of stimulant medications may pose risks for society. The threshold of drug availability that can lead to oversupply and consequent illicit use is unknown. There is little evidence that current levels of production have had a substantial effect on abuse. However, there is a need to be vigilant in monitoring the national indices of use and abuse of stimulants among high school seniors. One of the indices is the Drug Abuse Warning Network (DAWN). 5. What Are the Existing Diagnostic and Treatment Practices, and What Are the Barriers to Appropriate Identification, Evaluation, and Intervention?The American Academy of Child and Adolescent Psychiatry has published practice parameters for the assessment and treatment of ADHD. The American Academy of Pediatrics has formed a subcommittee to establish parameters for pediatricians, but those guidelines are not available at this time. Primary care and developmental pediatricians, family practitioners, (child) neurologists, psychologists, and psychiatrists are the providers responsible for assessment, diagnosis, and treatment of most children with ADHD. There is wide variation among types of practitioners with respect to frequency of diagnosis of ADHD. Data indicate that family practitioners diagnose more quickly and prescribe medication more frequently than psychiatrists or pediatricians. This may be due in part to the limited time spent making the diagnosis. Some practitioners invalidly use response to medication as a diagnostic criterion, and primary care practitioners are less likely to recognize comorbid (coexisting) disorders. The quickness with which some practitioners prescribe medications may decrease the likelihood that more educationally relevant interventions will be sought. Diagnoses may be made in an inconsistent manner with children sometimes being overdiagnosed and sometimes underdiagnosed. However, this does not affect the validity of the diagnosis when appropriate guidelines are used. Some practitioners do not use structured parent questionnaires, rating scales, or teacher or school input. Pediatricians, family practitioners, and psychiatrists tend to rely on parent rather than teacher input. There appears to be a “disconnect” between developmental or educational (school-based) assessments and health-related (medical practice-based) services. There is often poor communication between diagnosticians and those who implement and monitor treatment in schools. In addition, followup may be inadequate and fragmented. This is particularly important to ensure monitoring and early detection of any adverse effect of therapy. School-based clinics with a team approach that includes parents, teachers, school psychologists, and other mental health specialists may be a means to remove these barriers and improve access to assessment and treatment. Ideally, primary care practitioners with adequate time for consultation with such school teams should be able to make an appropriate assessment and diagnosis, but they should also be able to refer to mental health and other specialists when deemed necessary. What are the barriers to appropriate identification, evaluation, and intervention?Studies identify a number of barriers to appropriate identification, evaluation, and treatment. Barriers to identification and evaluation arise when central screening programs limit access to mental health services. The lack of insurance coverage for psychiatric or psychological evaluations, behavior modification programs, school consultation, parent management training, and other specialized programs presents a major barrier to accurate classification, diagnosis, and management of ADHD. Substantial cost barriers exist in that diagnosis results in out-of-pocket costs to families for services not covered by managed care or other health insurance. Mental health benefits are carved out of many policies offered to families, and thus access to treatment other than medication might be severely limited. Parity for mental health conditions in insurance plans is essential. Another cost implication lies in the fact that there is no funded special education category specifically for ADHD, which leaves these students underserved, and there is currently no tracking or monitoring of children with ADHD who are served outside of special education. This results in educational and mental health service sources disputing responsibility for coverage of special educational services. Barriers exist in relationship to gender, race, socioeconomic factors, and geographical distribution of physicians who identify and evaluate patients with ADHD. Other important barriers include those perceived by patients, families, and clinicians. These include lack of information, concerns about risks of medications, loss of parental rights, fear of professionals, social stigma, negative pressures from families and friends against seeking treatment, and jeopardizing jobs and military service. For health care providers, the lack of specialists and difficulties obtaining insurance coverage as outlined above present significant obstacles to care. 6. What Are the Directions for Future Research?Basic research is needed to better define ADHD. This research includes the following: (1) studies of cognitive development, cognitive processing, and attention/inattention in ADHD and (2) brain imaging studies before the initiation of medication and following the individual through young adulthood and middle age. Further research should be conducted with respect to the dimensional aspects of this disorder, as well as the comorbid (coexisting) conditions present in both childhood and adult ADHD. Therefore, an important research need is the investigation of standardized age- and gender-specific diagnostic criteria. The impact of ADHD should be determined. Studies in this regard include (1) the nature and severity of the impact on individuals, families, and society of adults with ADHD beyond the age of 20 and (2) determination of the financial costs related to diagnosis and care of children with ADHD. Additional studies are needed to develop a more systematized treatment strategy. These include:
Greater attention should be given to developing integrated programs for diagnosis and treatment. These include:
ConclusionsAttention deficit hyperactivity disorder or ADHD is a commonly diagnosed behavioral disorder of childhood that represents a major public health problem. Children with ADHD usually have pronounced difficulties and impairments resulting from the disorder across multiple settings. They can also experience long-term adverse effects on academic performance, vocational success, and social-emotional development. Despite progress in the assessment, diagnosis, and treatment of ADHD, this disorder and its treatment have remained controversial in many public and private sectors. The major controversy regarding ADHD continues to be the use of psychostimulants both for short-term and long-term treatment. Although an independent diagnostic test for ADHD does not exist, evidence supporting the validity of the disorder can be found. Further research will need to be conducted with respect to the dimensional aspects of ADHD, as well as the comorbid (coexisting) conditions present in both childhood and adult ADHD. Therefore, an important research need is the investigation of standardized age- and gender-specific diagnostic criteria. The impact of ADHD on individuals, families, schools, and society is profound and necessitates immediate attention. A considerable share of resources from the health care system and various social service agencies is currently devoted to individuals with ADHD. Often the services are delivered in a nonintegrated manner. Resource allocation based on better cost data leading to integrated care models needs to be developed for individuals with ADHD. Effective treatments for ADHD have been evaluated primarily for the short term (approximately 3 months). These studies have included randomized clinical trials that have established the efficacy of stimulants and psychosocial treatments for alleviating the symptoms of ADHD and associated aggressiveness and have indicated that stimulants are more effective than psychosocial therapies in treating these symptoms. Lack of consistent improvement beyond the core symptoms leads to the need for treatment strategies that utilize combined approaches. At the present time, there is a paucity of data providing information on long-term treatment beyond 14 months. Although trials combining drugs and behavioral modalities are under way, conclusive recommendations concerning treatment for the long term cannot be made easily. The risks of treatment, particularly the use of stimulant medication, are of considerable interest. Substantial evidence exists of wide variations in the use of psychostimulants across communities and physicians, suggesting no consensus among practitioners regarding which ADHD patients should be treated with psychostimulants. As measured by attention/activity indices, patients with varying levels and types of problems (and even possibly unaffected individuals) may benefit from stimulant therapy. However, there is no evidence regarding the appropriate ADHD diagnostic threshold above which the benefits of psychostimulant therapy outweigh the risks. Existing diagnostic and treatment practices, in combination with the potential risks associated with medication, point to the need for improved awareness by the health service sector concerning an appropriate assessment, treatment, and followup. A more consistent set of diagnostic procedures and practice guidelines is of utmost importance. Current barriers to evaluation and intervention exist across the health and education sectors. The cost barriers and lack of coverage preventing the appropriate diagnosis and treatment of ADHD and the lack of integration with educational services represent considerable long-term cost for society. The lack of information and education about accessibility and affordability of services must be remedied. Consensus Development Panel
Panel and Conference Chairperson Thomas Detre Professor and Chair of Psychiatry Western Psychiatric Institute and Clinic Department of Psychiatry University of Pittsburgh Pittsburgh, Pennsylvania
Professor of Pediatrics, Epidemiology, and Public Health Division of Infectious Diseases Department of Pediatrics Yale University School of Medicine New Haven, Connecticut
Professor Institute of Statistics and Decision Sciences Duke University Medical Center Durham, North Carolina
Director of Research Department of Psychiatry Henry Ford Health System Detroit, Michigan
Professor of Psychiatry and Pharmacology Duke University Medical Center Durham, North Carolina
Past Chair Utah Governor's Council for People With Disabilities Salt Lake City, Utah
Associate Professor of Neurology Division of Child Neurology Department of Neurology University of California, San Francisco San Francisco, California
Professor Department of Special Education Peabody College Vanderbilt University Nashville, Tennessee
Spencer T. Olin Professor of Psychiatry Department of Psychiatry Washington University School of Medicine St. Louis, Missouri
Visiting Professor Department of Psychiatry Cornell University Medical College New York, New York
Assistant Superintendent for Curriculum and Instruction Scottsdale Unified School District Phoenix, Arizona
Professor of Psychology Director of Clinical Training Department of Psychology University of Maryland College Park, Maryland
Pediatrician Milton Pediatrics Quincy, Massachusetts Speakers
"Matching Patients to Treatments" Professor of Clinical Psychiatry Director of Research NYU Child Study Center New York University School of Medicine New York, New York
"Individual and Family Barriers" Immediate Past National President Children and Adults With Attention Deficit Disorders Plantation, Florida
"Treatment Alternatives for ADHD" Professor Emeritus of Psychiatry Ohio State University, Columbus Sunbury, Ohio
"ADHD: Long-Term Course, Adult Outcome, and Comorbid Disorders" Director of Psychology Department of Psychiatry University of Massachusetts Medical Center Worcester, Massachusetts
"Pharmacotherapy of ADHD: Nonstimulant Treatments" Professor of Psychiatry, Harvard Medical School Chief, Joint Program in Pediatric Psychopharmacology Massachusetts and McLean General Hospitals Boston, Massachusetts
"The Prevalence and Cross-Cultural Validity of ADHD" Professor Clinical Psychiatry Columbia University Deputy Director Child Psychiatry New York State Psychiatric Institute New York, New York
"Risks and Mechanism of Action of Stimulants" Director Center for the Study of Psychiatry and Psychology Bethesda, Maryland
"Is ADHD a Valid Disorder?" Clinical Professor of Pediatrics University of Pennsylvania School of Medicine Division of General Pediatrics Children's Hospital of Philadelphia Philadelphia, Pennsylvania
"The Impact of ADHD on the Juvenile Justice System" Director of Research and Program Development Office of Juvenile Justice and Delinquency Prevention Washington, D.C.
"Overview of Attention Deficit Hyperactivity Disorder (ADHD)" Director, ADHD Program Department of Psychiatry Duke University Medical Center Durham, North Carolina
"Availability of Stimulant Medications: Nature and Extent of Abuse and Associated Harm" Associate Director for Medical Affairs Division of Clinical and Services Research National Institute on Drug Abuse National Institutes of Health Bethesda, Maryland
"Educational Policy: Educating Children With Attention Deficit Disorders" Director, Division of Research to Practice Office of Special Education Programs Office of Special Education and Rehabilitative Services U.S. Department of Education Washington, D.C.
"Diversion, Trafficking, and Abuse of Methylphenidate" Pharmacologist Drug and Chemical Evaluation Section Office of Diversion Control Drug Enforcement Administration Arlington, Virginia
"The Impact of ADHD on School Systems" Professor of Psychiatry and Biobehavioral Sciences Neuropsychiatric Hospital University of California, Los Angeles Los Angeles, California
"Stimulant Medications" Research Psychiatrist II New York State Psychiatric Institute Columbia University New York, New York
"Impairment: Childhood and Adolescence" Professor of Psychology Director of Clinical Psychology Training Program Department of Psychology University of California, Berkeley Berkeley, California
"A National Perspective on Treatments and Services for Children With ADHD" Chief of Child and Adolescent Services Research Services Research Branch National Institute of Mental Health National Institutes of Health Bethesda, Maryland
"Behavioral and Medication Treatments for ADHD: Comparisons and Combinations" Associate Director for Child and Adolescent Research National Institute of Mental Health National Institutes of Health Bethesda, Maryland
"The Impact of ADHD on Social and Vocational Functioning in Adults" Associate Professor Department of Psychology University of British Columbia Vancouver, British Columbia Canada
"Sensitization and the Risk of Exposure to Stimulant Medications" Professor and Chair Department of Physiology and Neuroscience Medical University of South Carolina Charleston, South Carolina
"Use of Services and Costs for Youth With ADHD and Related Conditions" Staunton Professor of Pediatrics and Psychiatry Child Services Research and Development Program University of Pittsburgh Pittsburgh, Pennsylvania
"Alcohol, Nicotine, Stimulants, and Other Drugs" Director of Clinical Psychology Department of Psychology New York State Psychiatric Institute New York, New York
"Current Diagnostic Schema/Core Dimensions" Professor of Psychiatry Chief of Psychology Department of Psychiatry University of Chicago Chicago, Illinois
"Stimulant Treatment as a Risk Factor for Nicotine Use and Substance Abuse" Professor Cognition and Development Area Director, School Psychology Program Graduate School of Education University of California, Berkeley Berkeley, California
"Risk of Treatment Versus Nontreatment" Professor Department of Psychiatry State University of New York at Stony Brook Stony Brook, New York
"Psychosocial Interventions" Professor and Director of Clinical Training Department of Psychology State University of New York at Buffalo Buffalo, New York
"Public Health Perspectives and Toxicological Issues Concerning Stimulant Medications" Epidemiologist Epidemiology Branch National Institute of Environmental Health Sciences National Institutes of Health Research Triangle Park, North Carolina
"Biological Bases of ADHD: Neuroanatomy, Genetics, and Pathophysiology" Professor of Pediatrics Department of Pediatrics University of California, Irvine Irvine, California
"Cognitive and Behavioral Correlates" Scientist Associate Professor of Psychiatry Brain and Behavior Program Research Institute for the Hospital for Sick Children University of Toronto Toronto, Ontario Canada
"ADHD and Risk for Substance Use Disorders" Associate Professor of Psychiatry Harvard Medical School Massachusetts General Hospital Boston, Massachusetts
"Current Assessment and Treatment Practices" Professor of Pediatrics Director, Division of Child Development Department of Pediatrics Vanderbilt University Nashville, Tennessee Planning Committee
Planning Committee Co-Chairperson Associate Director for Medical Affairs Division of Clinical and Services Research National Institute on Drug Abuse National Institutes of Health Bethesda, Maryland
Planning Committee Co-Chairperson Associate Director for Child and Adolescent Research National Institute of Mental Health National Institutes of Health Bethesda, Maryland
Immediate Past National President Children and Adults With Attention Deficit Disorders Plantation, Florida
Chief, Public Affairs and Science Reports Branch Office of Scientific Information National Institute of Mental Health National Institutes of Health Bethesda, Maryland
Society for Research in Child Development Fellow Developmental Psychopathology Research Branch National Institute of Mental Health National Institutes of Health Bethesda, Maryland
Health Science Administrator Division of Fundamental Neuroscience and Developmental Disorders National Institute of Neurological Disorders and Stroke National Institutes of Health Bethesda, Maryland
Director Division of Mental Health and Prevention of Substance Abuse World Health Organization Geneva, Switzerland
Medical Officer Division of Clinical and Services Research National Institute on Drug Abuse National Institutes of Health Bethesda, Maryland
Program Analysis and Management Officer Office of Medical Applications of Research National Institutes of Health Bethesda, Maryland
Director Office of Medical Applications of Research National Institutes of Health Bethesda, Maryland
Pharmacologist Drug and Chemical Evaluation Section Office of Diversion Control Drug Enforcement Administration Arlington, Virginia
Research Psychiatrist II New York State Psychiatric Institute Columbia University New York, New York
Director of Communications Office of Medical Applications of Research National Institutes of Health Bethesda, Maryland
Deputy Assistant Administrator Office of Diversion Control Drug Enforcement Administration Arlington, Virginia
Panel and Conference Chairperson Thomas Detre Professor and Chair of Psychiatry Western Psychiatric Institute and Clinic Department of Psychiatry University of Pittsburgh Pittsburgh, Pennsylvania
Professor of Psychiatry Chief of Psychology Department of Psychiatry University of Chicago Chicago, Illinois
Professor Department of Psychiatry State University of New York at Stony Brook Stony Brook, New York
Chief Child Development and Behavior Branch National Institute of Child Health and Human Development National Institutes of Health Bethesda, Maryland
Associate Commissioner for Health Affairs Food and Drug Administration Rockville, Maryland
Professor and Director of Clinical Training Department of Psychology State University of New York at Buffalo Buffalo, New York
Research Psychologist Treatment Research Branch Division of Clinical and Services Research National Institute on Drug Abuse National Institutes of Health Bethesda, Maryland
Epidemiologist Epidemiology Branch National Institute of Environmental Health Sciences National Institutes of Health Research Triangle Park, North Carolina
Special Assistant Division of Research to Practice Office of Special Education Programs U.S. Department of Education Washington, D.C.
Professor of Pediatrics and Neurology Department of Pediatrics Yale University School of Medicine New Haven, Connecticut
Deputy Director Office of Medical Applications of Research National Institutes of Health Bethesda, Maryland
Chief Child and Adolescent Treatment and Preventive Intervention Research Branch Division of Services and Intervention Research National Institute of Mental Health National Institutes of Health Bethesda, Maryland
Associate Professor of Psychiatry Harvard Medical School Massachusetts General Hospital Boston, Massachusetts Lead Organizations
John H. Ferguson, M.D. Director
Alan I. Leshner, Ph.D. Director
Steven E. Hyman, M.D. Directo Supporting Organizations
Kenneth Olden, Ph.D. Director
Duane Alexander, M.D. Director
Michael A. Friedman, M.D. Acting Commissioner
U.S. Department of Education Thomas Hehir, Ed.D. Director BibliographyThe speakers listed above identified the following key references in developing their presentations for the consensus conference. A more complete bibliography prepared by the National Library of Medicine (NLM) at NIH, along with the references below, was provided to the consensus panel for their consideration. The full NLM bibliography is available at the following Web site: http://www.nlm.nih.gov/pubs/cbm/adhd.html. OVERVIEW AND INTRODUCTION
ADHD AS A DISORDER IN CHILDREN, ADOLESCENTS, AND ADULTS
IMPACT
SAFETY AND EFFICACY OF TREATMENTS -- SHORT AND LONG TERM
SUBSTANCE ABUSE RISKS OF STIMULANT TREATMENTS
EXISTING PRACTICES AND BARRIERS REGARDING ASSESSMENT AND TREATMENT
|
|
Contact
Consensus Program | Privacy Notice | Disclaimer | Accessibility | Contact NIH |
